# ZUMA-22 (NCT05371093)

> Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05371093
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Kite, A Gilead Company
- Conditions: Relapsed/Refractory Follicular Lymphoma
- Interventions: Axicabtagene Ciloleucel; Cyclophosphamide; Fludarabine; Lenalidomide; Rituximab; Doxorubicin; Vincristine; Prednisone; Bendamustine
- Enrollment: 231
- Primary outcome: Progression-free Survival (PFS) as Assessed by Blinded Central Assessment per Lugano Classification

## Commentary we found

- YouTube: 14
- Podcasts: 6
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=zuma-22-nct05371093

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05371093", "email": "<work email>"}; the inbox owner confirms by the emailed link.